Search
Cyclophosphamide Treatment Options
A collection of 2185 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the United States . Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
301 - 312 of 2185
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Therapy
Unique Treatment for High Blood Pressure
Worried about high blood pressure? Think beyond typical high blood pressure treatments.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
People who may be candidates for this procedure:
• Are at least 18 years old
• Have been unable to manage their high blood pressure with medications or lifestyle changes alone¹
Learn about a safe and effective procedure that may help reduce high blood pressure. See if you qualify today.
¹ Kandzari DE, et al. J Am Coll Cardiol. Nov 7, 2023;82(19):1809-1823.
Conditions:
High Blood Pressure
High Blood Pressure (& [Essential Hypertension])
High Blood Pressure (Hypertension).
Hypertension
Essential Hypertension
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Trial
Discover Clinical Trials In Your Area (Compensation Provided)
Recruiting
Clinical trials in your area are actively enrolling — and they compensate you for your time. Finding the right one has never been easier.
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
- Matched to trials in your zip code
- Compensation for time & travel
- Free or low-cost treatments available
- No experience or medical background needed
- Takes just 30 seconds to see if you qualify
Conditions:
Healthy
Healthy Volunteers
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
Active Not Recruiting
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/30/2025
Locations: Research Site, Tucson, Arizona +254 locations
Conditions: Diffuse Large B-Cell Lymphoma
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Recruiting
ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).
The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2025
Locations: University of California San Diego, San Diego, California +8 locations
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Allo HSCT Using RIC and PTCy for Hematological Diseases
Recruiting
This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis.
Gender:
ALL
Ages:
75 years and below
Trial Updated:
06/27/2025
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Recruiting
Background:
In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70.
Objectives:
To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe.
Eligibility:
Adults age 18... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
06/27/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
CER-1236 in Patients With Acute Myeloid Leukemia (AML)
Recruiting
This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/27/2025
Locations: Colorado Blood Cancer Institute, Denver, Colorado +2 locations
Conditions: AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Recruiting
This phase I trial studies the effects of CD-19 directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of patients with B cell malignancies that have come back (recurrent) or have not responded to treatment (refractory). CD-19 CAR-T cells use some of a patient's own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill cancer cells. Some T cells are removed from the blood, and then laboratory, researchers will put a new gene i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
Recruiting
This phase II trial studies the how well donor stem cell transplant works in treating patients with high risk hematologic malignancies. Giving total-body irradiation and chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
Recruiting
This is a multicenter Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and an FDAapproved CAR-T product Tisagenlecleucel/Kymriah, Axicabtagene Ciloleucel/Yescarta, or lisocabtagene maraleucel/Breyanzi) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3 who are at a higher risk for failure of CAR-T therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota
Conditions: DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, DLBCL Arising From Follicular Lymphoma
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
Active Not Recruiting
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have lived longer and had better responses to treatment) when compared to individuals treated with standard chemotherapy.
Past studies conducted at the MIRT have shown that participants presenting to MIRT who have already received treatment for myeloma tend to have shorter rem... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/26/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Myeloma
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Recruiting
This feasibility trial studies how well daratumumab in combination with dose-adjusted etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-EPOCH) works in treating patients with newly diagnosed stage I-IV plasmablastic lymphoma. Plasmablastic lymphoma cells have high levels of a protein called CD38. Daratumumab is a monoclonal antibody that specifically targets CD38 expressing cells, and may help the body's immune system attack the cancer and interfere... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of Miami Miller School of Medicine, Miami, Florida +7 locations
Conditions: Ann Arbor Stage I Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Plasmablastic Lymphoma
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
Recruiting
This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite treatment with platinum therapy (platinum resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize TAG72, a protein on the surface of tumor cells. These TAG72... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Platinum-Resistant Ovarian Carcinoma
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Recruiting
This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Mayo Clinic - Arizona, Scottsdale, Arizona +33 locations
Conditions: Lymphoma, B-Cell
301 - 312 of 2185